7 Results for "

loss-of-function

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "loss-of-function" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-100886
CAS No.: 1375469-38-7
Purity:  98.02%
Target:  

PI3K Apoptosis

Research Areas:  

Cancer

BAY1082439 is an orally bioavailable, selective PI3Kα/β/δ inhibitor. BAY1082439 also inhibits mutated forms of PIK3CA. BAY1082439 is highly effective in inhibiting Pten-null prostate cancer growth .
loading...
    loading...
Cat. No.: HY-149555
CAS No.: 2278265-85-1
Purity:  99.94%
DNL343 is a potent, selective, orally active and brain-penetrant activator of eukaryotic initiation factor eIF2B. DNL343 inhibits the activity of the integrated stress response (ISR) in the central nervous system (CNS) and reverses neurodegeneration and neuroinflammation. DNL343 also prevents motor dysfunction and premature death in eIF2B loss-of-function (LOF) mutant mice. DNL343 can be used in the study of neurodegenerative diseases .
loading...
    loading...
Cat. No.: HY-132893
CAS No.: 2830555-70-7
Target:  

TAM Receptor

Research Areas:  

Neurological Disease Cancer

AZ14145845 is an orally active dual-target type 1½ kinase inhibitor of Mer/Axl, which inhibits Mer kinase (pIC50 = 9.0) and Axl kinase (pIC50 = 7.9) with high selectivity over Flt3 and Tyro3. AZ14145845 suppresses Mer- and Axl-dependent proliferation in Ba/F3 cells and inhibits efferocytosis in macrophages. AZ14145845 reduces the phagocytosis of photoreceptor outer segments by polarized human retinal epithelial cells. AZ14145845 inhibits tumor growth and induces tumor regression in vivo, and its combination with anti-PD1 antibody and ionizing radiation improves the survival rate of mice with colorectal cancer. AZ14145845 causes retinal degeneration in mice, with pathological changes similar to those in MERTK loss-of-function models. AZ14145845 can be used in studies related to retinal degeneration, lymphoma and colorectal cancer .
loading...
    loading...
Cat. No.: HY-159709
CAS No.: 2765519-47-7
Target:  

Liposome

Research Areas:  

Metabolic Disease

VL-422 is an ionizable cationic lipid. VL-422 delivers CRISPR complementary single-guide RNA (sgRNA) and Cas9 mRNA to enable in vitro and in vivo gene editing. LNPs containing VL-422 loaded with Cas9 mRNA and sgRNA targeting the ANGPTL3 gene induce the deletion of premature stop codons within the ANGPTL3 gene in the liver of cynomolgus monkeys. Loss-of-function of ANGPTL3 leads to decreased levels of LDL, HDL and cholesterol in plasma. The VL-422 delivery system can be used for the research of gene editing strategies targeting lipid metabolism diseases .
loading...
    loading...
Cat. No.: HY-115726
CAS No.: 2085780-87-4
Purity:  99.45%
Target:  

γ-secretase Amyloid-β

Research Areas:  

Neurological Disease

FRM-024 is a central nervous system-penetrant, orally active γ-secretase modulator and Aβ42 lowering agent. FRM-024 is used for the research of familial Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-143615
CAS No.: 2662622-44-6
Target:  

RET

Research Areas:  

Cancer

RET-IN-10 is a potent inhibitor of RET. RET loss of function mutations leads to Hirschsprung's disease, while its gain of function mutations is associated with a variety of human tumors. RET-IN-10 has the potential for the research of cancer diseases (extracted from patent WO2021135938A1, compound 18) .
loading...
    loading...
Cat. No.: HY-100886R
CAS No.: 1375469-38-7
Research Areas:  

Cancer

BAY1082439 (Standard) is the analytical standard of BAY1082439 (HY-100886). This product is intended for research and analytical applications. BAY1082439 is an orally bioavailable, selective PI3Kα/β/δ inhibitor. BAY1082439 also inhibits mutated forms of PIK3CA. BAY1082439 is highly effective in inhibiting Pten-null prostate cancer growth .
loading...
    loading...